Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Interpreting the ADAURA data

Sanjay Popat • 11 Jun 2020
ASCO 2020
Lung Cancer Non-Small Cell Lung Cancer Osimertinib
ADAURA

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, gives his thoughts on the ADAURA study (NCT02511106) data presented at ASCO 2020. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sanjay Popat

2:33
Reflecting on BTOG 2024: networking and multidisciplinary collaboration
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals